STOCK TITAN

Adage Capital discloses 6.35% Minerva Neurosciences (NERV) stake via 2.84M shares

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Adage Capital Management and affiliates reported a 6.35% beneficial stake in Minerva Neurosciences common stock. The group is deemed to beneficially own 2,838,000 shares of common stock, based on 43,274,398 shares outstanding as of December 23, 2025.

This amount includes 1,419,000 shares issuable upon conversion of preferred stock underlying warrants held by Adage Capital Partners. All voting and dispositive powers are shared among Adage Capital Management, Robert Atchinson, and Phillip Gross, and the securities are described as acquired and held in the ordinary course of business, not for the purpose of influencing control.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Includes 1,419,000 shares of Common Stock (as defined in Item 2(a)) issuable upon conversion of shares of preferred stock issuable upon exercise of warrants.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes 1,419,000 shares of Common Stock issuable upon conversion of shares of preferred stock issuable upon exercise of warrants.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes 1,419,000 shares of Common Stock issuable upon conversion of shares of preferred stock issuable upon exercise of warrants.


SCHEDULE 13G



Adage Capital Management, L.P.
Signature:/s/ Robert Atchinson
Name/Title:By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
Date:02/12/2026
Robert Atchinson
Signature:/s/ Robert Atchinson
Name/Title:Robert Atchinson, individually
Date:02/12/2026
Phillip Gross
Signature:/s/ Phillip Gross
Name/Title:Phillip Gross, individually
Date:02/12/2026
Exhibit Information

Exhibit 99.1: Joint Filing Agreement

FAQ

What stake does Adage Capital report in Minerva Neurosciences (NERV)?

Adage Capital and related reporting persons report beneficial ownership of 2,838,000 Minerva Neurosciences common shares, representing 6.35% of the class. This percentage is calculated against 43,274,398 shares outstanding as of December 23, 2025, as disclosed in a company prospectus.

How is the 2,838,000-share Minerva Neurosciences (NERV) position composed?

The reported 2,838,000-share position includes 1,419,000 shares of common stock issuable upon conversion of preferred stock underlying warrants. The remainder reflects currently outstanding common shares held for the accounts managed by Adage Capital Partners and associated entities.

Who are the reporting persons in this Minerva Neurosciences (NERV) Schedule 13G?

The reporting persons are Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross. They report shared voting and shared dispositive power over 2,838,000 Minerva Neurosciences common shares, with no sole voting or sole dispositive power indicated for any reporting person.

What voting and dispositive powers are reported for the NERV shares?

Each reporting person lists zero sole voting and sole dispositive power, but 2,838,000 shares of shared voting and shared dispositive power. This means decisions on voting and disposition of the Minerva Neurosciences shares are made jointly under the described investment management and control structure.

On what share count is Adage’s 6.35% Minerva Neurosciences (NERV) ownership based?

The 6.35% beneficial ownership is calculated using 43,274,398 Minerva Neurosciences common shares outstanding as of December 23, 2025. That outstanding share figure comes from a company prospectus filed under Rule 424(b)(3) with the Securities and Exchange Commission.

Does Adage Capital seek to influence control of Minerva Neurosciences (NERV)?

The reporting persons certify the securities were acquired and are held in the ordinary course of business, not for changing or influencing control of Minerva Neurosciences. They also state the holdings are not part of any transaction intended to affect control, aside from limited nomination-related activities.